OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC)
2021 ◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 22
(5)
◽
pp. 440-448
◽